Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

AAN updated guideline on how to best treat essential tremor

The American Academy of Neurology is releasing an updated guideline on how to best treat essential tremor, which is the most common type of tremor disorder and is often confused with other movement disorders such as Parkinson's disease.

20 Oct 2011

FUTURAGE project to tackle Europe's ageing population over the next 10 years

An ambitious project led by researchers at the University of Sheffield is set to tackle the grand challenge of Europe's ageing population over the next 10 years.

19 Oct 2011

Melbourne Brain Centre to open on Monday

Melbourne will become a magnet for the world's best and brightest brain researchers after the official opening of the Melbourne Brain Centre at The University of Melbourne Parkville by the Premier Ted Baillieu and Federal MP Michael Danby on Monday.

19 Oct 2011

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $0.91 in the second quarter of fiscal 2012. Reported earnings per share in the second quarter of fiscal 2011 were $1.00.

18 Oct 2011

UTA technology could reduce time and cost to finding a cure for Alzheimer's

Technology developed by researchers at The University of Texas at Austin could significantly reduce the time and cost to finding a cure for Alzheimer's disease and help answer one of the greatest biological questions: why do we age?

18 Oct 2011

Commercialization strategies for next-generation medicines

The Center for Biotechnology at Stony Brook University, in collaboration with Demy-Colton Life Science Advisors, and key opinion leaders from the biotech and biopharmaceutical industries, academia, medical research foundations, and investment community, has organized a two-day event to forge partnerships to accelerate the development of new treatments for some of the world's most devastating diseases affecting millions.

18 Oct 2011

Hypertension drugs might reduce occurrence of Alzheimer's

Within the next 20 years it is expected the number of people with Alzheimer's disease (AD) will double from its current figure of half a million to one million. A new study has looked at whether certain types of drugs used to treat high blood pressure, also called hypertension, might have beneficial effects in reducing the number of new cases of Alzheimer's disease each year.

18 Oct 2011

Accera identifies genetic profile of AD patients with heightened response to Axona

Accera, Inc., a biotech company specializing in cognitive health, announced today that it has identified the genetic profile of Alzheimer’s disease (AD) patients who have a high probability of responding to Axona (AC-1202), a prescription medical food product available at pharmacies nationwide.

18 Oct 2011

HSV1 drugs could slow progression of Alzheimer's disease

Antiviral drugs used to target the herpes virus could be effective at slowing the progression of Alzheimer's disease (AD), a new study shows.

From The University of Manchester 18 Oct 2011

Inhaled anesthetics do not increase incidence of postoperative delirium

A study presented at ANESTHESIOLOGY 2011 in Chicago this week offered firm evidence that commonly used inhaled anesthetics such as isoflurane do not increase the incidence of postoperative delirium, which can affect how well some patients recover after surgery.

18 Oct 2011

Brain tumour discovery offers drug treatment hope

Australian scientists have played a key role in the identification of a new biochemical mechanism that allows brain tumours to survive and grow, offering hope of new drug treatments for some of the most aggressive tumours.

17 Oct 2011

Johns Hopkins Brain Science Institute organizes Drug Discovery in Academia symposium

A symposium to be hosted by the Johns Hopkins Brain Science Institute (BSi) on Oct. 18 at the Baltimore Convention Center will bring together the pharmaceutical industry and academic-based research institutions with the common goal of exploring how the two can best work together to enhance and facilitate the discovery of new drugs.

15 Oct 2011

Obese post-menopausal women outperform normal weight counterparts in cognitive tasks

Obesity has been associated with cognitive decline, characterized by a deterioration of mental abilities that involve memory, language, and thought-processing speed.

14 Oct 2011

First physical evidence that bilingualism delays onset of Alzheimer's

Researchers at St. Michael's Hospital have found that people who speak more than one language have twice as much brain damage as unilingual people before they exhibit symptoms of Alzheimer's disease. It's the first physical evidence that bilingualism delays the onset of the disease.

14 Oct 2011

NIH awards Scripps Research scientist for research into Type I diabetes

A scientist at The Scripps Research Institute has been awarded $4.2 million from the National Institutes of Health in a program to advance what the agency calls "bold and creative research" into Type I diabetes.

14 Oct 2011

NIH awards Salk Institute $4.5M to establish new Neuroscience Core Center

The National Institutes of Health has announced that the Salk Institute will receive $4.5 million to establish a Neuroscience Core Center, a new research center intended to accelerate brain research that lays the foundation for developing new ways to treat congenital brain defects and neurological diseases.

14 Oct 2011

Faster cerebral cortex growth in infancy may lead to higher intelligence

New research suggests the growth rate of the brain's cerebral cortex in babies born prematurely may predict how well they are able to think, speak, plan and pay attention later in childhood. The research is published in the October 12, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology.

14 Oct 2011

October is designated as Lewy Body Dementia month

The month of October is designated as Lewy Body Dementia month. Lewy body dementia (LBD) is a degenerative brain disease that progressively impairs thinking and movement, while impacting behavior and sleep. Although it affects an estimated 1.3 million people in the U.S., LBD is under-recognized, under-diagnosed and under-treated. It is most often misdiagnosed as Alzheimer's or Parkinson's disease.

13 Oct 2011

AAN Foundation launches new PSA on finding cure for brain disease

With one in six people in the United States now affected by brain disease such as dementia, multiple sclerosis and epilepsy, the American Academy of Neurology Foundation is marking its 20th anniversary with the launch of a new public service announcement (PSA) to raise awareness about the need for more research to cure brain disease.

12 Oct 2011

AFFiRiS receives MJFF grant for clinical study of AFFITOPE PD01

The Michael J. Fox Foundation (MJFF) today announced that it has awarded $1.5 million to AFFiRiS AG, a Vienna, Austria-based biotech company, for a clinical study of AFFITOPE PD01, a first-of-its-kind Parkinson's disease (PD) vaccine.

12 Oct 2011